Avita Medical, Inc. · NASDAQ:RCEL
Avita Medical — Q2 2024 Earnings Presentation
22 slides from Avita Medical's earnings presentation, Aug 14, 2024
Slide 1: Investor Presentation Q2 2024
NASDAQ: RCEL ASX: AVH For personal use only Investor Presentation Q2 2024
Slide 2: Forward-Looking Statements & Legal Disclaimers
Forward-Looking Statements & Legal Disclaimers 2024.Q4 v9 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to significant risks and uncertainties that could cause actual resul
Slide 3: Our Company
Our Company W H O W E AR E O U R M I SS I O N OUR VISION For personal use only AVITA Medical is a commercial-stage Produce innovative approaches to wound Build a global broad-based wound care regenerative medicine company care and healing skin, enabling company with a portfolio that addresses the tr
Slide 4: Strategic Transformation
Strategic Transformation P O RT FO L I O E X PAN S I O N I N N OVAT I O N ADVAN C E M E N T For personal use only Develop and integrate new products to complement Continue to innovate, expanding the treatment our RECELL-centric portfolio, addressing the full capabilities of our portfolio and setting
Slide 5: Leadership
Leadership For personal use only Nicole Kelsey Debbie Garner Jim Corbett David O’Toole Chief Legal and Compliance Robin VanDenburgh SVP, Global Marketing & Chief Executive Officer* Chief Financial Officer* Officer and Corporate SVP, U.S. Commercial Sales Strategy 30+ Years of Experience 30+ Years of
Slide 6: Technology Overview: RECELL
For personal use only Technology Overview: RECELL P6
Slide 7: RECELL Platform
RECELL Platform 2024 2025 For personal use only R EC E L L GO • Two components: multi-use, AC-powered RECELL GO Processing Device (“RPD”) and a RECELL GO UP TO ~10% TOTAL BODY SURFACE UP TO ~2.5% TOTAL BODY Preparation Kit (“RPK”) AREA SURFACE AREA • RPK includes: single-use RECELL GO Cartridge, • L
Slide 8: Maximizing Operating Room Efficiency with Multiple Devices
Maximizing Operating Room Efficiency with Multiple Devices For personal use only Treating a burn injury 10% - 20% TBSA Treating a burn injury 20-30% TBSA Treating a burn injury 30-40% TBSA P8
Slide 9: How is RECELL GO Going?
How is RECELL GO Going? You can see for yourself. For personal use only Treating a burn injury 50% - 60% TBSA P9
Slide 10: RECELL: Market Sizing for Burn and Full-Thickness Skin Defects
RECELL: Market Sizing for Burn and Full-Thickness Skin Defects Market Size Additional Market Opportunity Prior to FDA Approval 1 with FDA Approved Expanded Indication of FTSD1 For personal use only Traumatic Wounds Traumatic Wounds Surgical Wounds • Degloving (Open Wounds) 99,000 • Gun Shot Wounds 1
Slide 11: Update on Full-Thickness Skin Defect Launch
Update on Full-Thickness Skin Defect Launch RECELL FOR FULL-THICKNESS SKIN DEFECTS For personal use only ACCOUNT STATUS 60 52 50 Number of Accounts 40 37 31 30 22 20 10 6 0 Q1 2024 Q2 2024 QTD Q3 2024* New Accounts VAC Approved, No Order† VAC Evaluation Stage VAC Decision Stage * As of July 31, 2024
Slide 12: Global Commercialization Strategy for RECELL
Global Commercialization Strategy for RECELL FOCUSED MARKET For personal use only • Australia • European Union • Japan STRATEGY • Plan to expand exclusively through third-party distribution partners UPDATE AS OF JULY 31, 2024 • We have agreements with Germany, Austria, Switzerland, Belgium, Holland,
Slide 13: Transforming into a Broad Wound Care Company
For personal use only Transforming into a Broad Wound Care Company P 13
Slide 14: Strategic Transformation – Continuum of Wound Care
Strategic Transformation – Continuum of Wound Care CONTINUUM OF BURN AND FULL-THICKNESS SKIN DEFECT For personal use only WOUND CARE WOUND DEPTH WOUND BED WOUND BED DERMAL EPIDERMAL DRESSINGS W O U N D S CA R ASSESSMENT P R E PA R AT I O N H E M O STA S I S R E P L AC E M E N T/ R E P L AC E M E N T
Slide 15: Product Compatibility for Wound Care
Product Compatibility for Wound Care CLINICAL PRESENTATION : FULL-THICKNESS SKIN DEFECT WITH CONCERN FOR INFECTION For personal use only Dressing optimized for protection and moisture PermeaDerm by Stedical management RECELL + meshed split- Robust closure using significantly less skin thickness skin
Slide 16: Strategy with Regenity
Strategy with Regenity On July 31, 2024, AVITA Medical entered exclusive multi-year development and distribution For personal use only agreement with Regenity Biosciences P RO D U CT • Unique collagen-based dermal matrix PAT H TO CO M M E RC I AL I ZAT I O N • 510(k) Clearance: expect Regenity to re
Slide 17: Financials
For personal use only Financials P 17
Slide 18: Financial Update
Financial Update Q 2 2024 F I N AN C I A L R ES U LTS 2024 F I N AN C I AL GU I DAN C E For personal use only Commercial revenue: Commercial revenue: • $15.1 million, an increase of ~29% year-over-year • Q3 2024: expect $19 to $20 million, representing ~40% to 48% growth year-over-year Gross profit
Slide 19: Quarterly Commercial Revenue
Quarterly Commercial Revenue STRONG COMMERCIAL GROWTH use only $20,000 $19,500 1 $18,000 Revenue (in thousands) $16,000 $15,133 $14,097 $14,000 $13,546 personal $12,000 $11,687 $11,069 $10,458 $10,000 $8,999 $9,364 $8,000 51% 29% 40% 42% 50% 6% 44%1 Year-Over-Year Growth Commercial $6,000 For $4,000
Slide 20: Summary
For personal use only Summary P 20
Slide 21: Looking Ahead: 2H 2024 Priorities
Looking Ahead: 2H 2024 Priorities > SA L ES E X ECU T I O N • Expand into trauma centers with full-thickness skin defect indication by advancing through VAC approval For personal use only process; targeting at least 45 new accounts per quarter • Continue to drive penetration, adoption, and growth wi
Slide 22: For personal use only
For personal use only